Endoscopic stenting for malignant biliary obstruction
Executive Summary
Malignant biliary obstruction—a narrowing of the bile ducts caused by tumor-related strictures—presents primarily as painless jaundice and requires prompt decompression to alleviate symptoms and prevent complications like cholangitis. Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the primary intervention for both palliative and, in specific cases, preoperative management.
Self-expandable metallic stents (SEMS) are the preferred choice for patients with a prognosis greater than three months due to superior patency (typically >270 days) and lower rates of reintervention compared to plastic stents. While uncovered SEMS offer versatility and lower migration rates (0–2%), they are susceptible to tumor ingrowth. Covered SEMS reduce ingrowth but carry higher risks of migration (6–8%) and cholecystitis. Selection between stent types depends on the location of the obstruction (distal vs. hilar), tumor type, and whether the gallbladder is intact. Successful biliary decompression is defined by the relief of cholestasis and, in hilar cases, the drainage of at least 50% of the total liver volume to improve overall survival.
1. Overview and Pathophysiology
Malignant biliary obstruction occurs when tumors cause strictures in the bile ducts. These obstructions are categorized based on their anatomical location:
Distal Common Bile Duct Obstruction: Causes include pancreatic cancer (primarily in the head and uncinate process), cholangiocarcinoma, ampullary tumors, or external compression from lymph nodes.
Proximal (Hilar) Obstruction: Often caused by hilar cholangiocarcinoma (Klatskin tumor), gallbladder carcinoma, metastatic disease, or local extension of pancreatic cancer.
The primary clinical presentation is painless jaundice, though symptoms of cholestasis such as pruritus and dark urine are common.
2. Indications and Contraindications
2.1 Palliative Drainage
Indicated for patients with surgically incurable cancer to:
Relieve symptoms of cholestasis (jaundice, pruritus).
Treat or prevent acute cholangitis.
Optimize medical status before beginning chemoradiation therapy.
2.2 Preoperative Drainage
Biliary stenting prior to surgical resection is reserved for resectable cases involving:
Acute cholangitis.
Debilitating pruritus.
Anticipated surgical delays of >2 weeks (e.g., planned neoadjuvant chemotherapy).
2.3 Contraindications
Inability to tolerate monitored anesthesia care or general anesthesia.
Hemodynamic instability.
Total gastrointestinal (luminal) obstruction (limits access to the biliary orifice).
3. Pre-procedural and Procedural Standards
3.1 Patient Preparation
Medication Management: Aspirin and NSAIDs generally do not need to be discontinued. Anticoagulants and antiplatelet agents require individualized management.
Antibiotic Prophylaxis: Required for patients at risk of incomplete drainage (e.g., hilar obstruction). Common regimens include Ciprofloxacin (500mg oral or 400mg IV) or Amoxicillin-clavulanate (1750mg oral).
3.2 Sphincterotomy
Routine biliary sphincterotomy prior to SEMS placement is generally avoided. Evidence suggests it does not lower the risk of post-ERCP pancreatitis and significantly increases the risk of bleeding (Risk Ratio 7.43).
4. Stent Technology and Selection
4.1 Stent Types and Characteristics
4.2 Material and Design
Materials: Nitinol (nickel-titanium) is common for shape retention; Platinol (platinum core) offers flexibility in tortuous ducts.
Sizing: SEMS are available in diameters of 5 to 12 mm (15–36 Fr). Patency is generally better with larger diameters (8–10 mm).
5. Clinical Management Strategies
5.1 Distal Biliary Obstruction
For unresectable distal disease:
Survival >3 Months: SEMS (8–10 mm) are recommended. SEMS reduce the risk of stent occlusion (OR 0.48) and cholangitis (OR 0.46) compared to plastic.
Survival ≤3 Months: Plastic stents are an acceptable alternative for short-term drainage.
5.2 Hilar (Proximal) Obstruction
Management is technically complex and requires a multidisciplinary team.
Stent Selection: Uncovered SEMS are preferred to avoid occluding the contralateral biliary system.
Drainage Volume: Draining ≥50% of the total liver volume is associated with improved survival.
Bilateral Stenting: When both liver lobes are obstructed, bilateral SEMS are placed if technically feasible to maximize drainage.
5.3 Resectable Disease
Short SEMS (40–60 mm) are typically used if surgery is delayed for neoadjuvant therapy. This approach is associated with fewer reinterventions (3% vs. 15% for plastic stents) without increasing surgical morbidity.
6. Adverse Events and Complications
6.1 Stent Occlusion
The most common complication, manifesting as cholestasis or cholangitis.
Tumor Ingrowth: Primary cause for uncovered SEMS (occurs in ~27% of cases).
Tumor Overgrowth: More common in covered SEMS (Relative Risk 2.02).
Biliary Sludge: Can impact both metal and plastic stents.
Management: Treatment involves balloon sweeping or placing a second "stent-within-a-stent" (either plastic or metal).
6.2 Stent Migration
Reported in 6–8% of covered SEMS. Diagnosis is confirmed via CT or radiograph, and management requires ERCP-guided removal or replacement.
6.3 Specialized Risks
Cholecystitis: Occurs in approximately 3–8% of patients with an intact gallbladder if a SEMS (especially covered) is placed across the cystic duct orifice.
Post-ERCP Pancreatitis: A risk of the procedure itself rather than the specific stent type used.
Bleeding and Perforation: Rare complications; bleeding may occur from duodenal wall irritation or hemobilia.
7. Alternative Interventions
For patients in whom ERCP-guided drainage fails:
EUS-guided Choledochoduodenostomy (EUS-CDS): A safe and effective alternative using lumen-apposing metal stents (LAMS). Success rates are high (93% technical success), with clinical outcomes comparable to ERCP.
Percutaneous Drainage: Utilized when endoscopic routes are not feasible, particularly in complex hilar cases.
